News Column

Investigators at Mayo Clinic Have Reported New Data on POEMS Syndrome

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- New research on Blood Protein Disorders is the subject of a report. According to news originating from Rochester, Minnesota, by NewsRx correspondents, research stated, "POEMS syndrome is a rare plasma cell dyscrasia presenting with polyneuropathy and other systemic findings. Patients with 1 to 3 bone lesions and negative bone marrows are often treated with involved field radiation therapy as the initial and potentially definitive therapy."

Our news journalists obtained a quote from the research from Mayo Clinic, "Long-term outcomes of patients treated with this approach have not been systematically studied. Of the 146 patients with POEMS syndrome seen at the Mayo Clinic between January 1999 and September 2011, 38 (26%) were given targeted radiation as their initial primary therapy and are the ones studied here. The median number of bone lesions was 1 (range: 1-6). The median dose of radiation administered was 45 Gy (range: 35-54 Gy). Complete or partial hematologic, vascular endothelial growth factor, fluorodeoxyglucose-positron emission tomography, and clinical responses were documented in 31%, 14%, 22%, and 47%, respectively. With median follow-up of 43 months, the 4-year overall survival is 97% and event-free survival is 52%. Risk factors for needing salvage therapy included reduced pulmonary diffusing capacity of carbon monoxide and increased urinary total protein. The presence of 3 lesions compared with 1 or 2 did not increase risk for treatment failure."

According to the news editors, the research concluded: "Among selected patients with POEMS syndrome, radiation produces durable, meaningful responses."

For more information on this research see: Outcomes of patients with POEMS syndrome treated initially with radiation. Blood, 2013;122(1):68-73. (American Society of Hematology -; Blood -

The news correspondents report that additional information may be obtained from M.S. Humeniuk, Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States. Additional authors for this research include M.A. Gertz, M.Q. Lacy, R.A. Kyle, T.E. Witzig, S.K. Kumar, P. Kapoor, J.A. Lust, S.R. Hayman, F.K. Buadi, S.V. Rajkumar, S.R. Zeldenrust, S.J. Russell, D. Dingli, Y. Lin, N. Leung and A. Dispenzieri (see also Blood Protein Disorders).

Keywords for this news article include: Rochester, Minnesota, United States, Bone Research, POEMS Syndrome, Paraproteinemias, Polyneuropathies, Radiation Therapy, Hematologic Diseases, Neuromuscular Diseases, Blood Protein Disorders, North and Central America, Hemic and Lymphatic Diseases, Peripheral Nervous System Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters